Vir Biotechnology Identifies Two Antibodies with Therapeutic Potential for COVID-19
The US biotech Vir Biotechnology announced it will proceed with two antibodies with the potential for the prevention and treatment of COVID-19. The company plans to initiate human clinical trials in the next three to five months.
According to Vir Biotechnology, it has identified several human monoclonal antibodies (mAb) with therapeutic potential for COVID-19. The lead antibody has been tested in two different laboratories for its ability to neutralize SARS-CoV-2. Importantly, this antibody binds to an epitope on SARS-CoV-2 which is also expressed on SARS-CoV-1, the virus which is responsible for the Severe Acute Respiratory Syndrome (SARS). This high degree of conservation among different types of Coronaviruses indicates a relatively low risk for the development of resistance to the antibody should the virus mutate.
In order to speed up the clinical development process, the company’s lead candidate was transferred to WuXi Biologics and Biogen several weeks ago. Vir Biotechnology expects the initiation of clinical trials in the next three to five months.
The full press release of Vir Biotechnology can be accessed here.